Filing Details
- Accession Number:
- 0001225208-14-008076
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-03-11 18:21:16
- Reporting Period:
- 2014-03-10
- Filing Date:
- 2014-03-11
- Accepted Time:
- 2014-03-11 17:21:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 810509 | Navidea Biopharmaceuticals Inc. | NAVB | In Vitro & In Vivo Diagnostic Substances (2835) | 311080091 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1456549 | O Frederick Cope | 5600 Blazer Parkway Suite 200 Dublin OH 43017 | Svp | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-03-10 | 15,000 | $1.96 | 75,814 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 8,637 | Indirect | By 401(k) |
Footnotes
- Sales were effected to generate funds required to cover tax obligations arising from expiring options or the vesting of shares of restricted stock. The transaction is matchable under Section 16(b) of the Securities Exchange Act with Dr. Cope's purchase of 3,500 shares of common stock at $1.43 per share on November 8, 2013. As a result, Dr. Cope will pay the company $1,855 representing the full amount of the profit realized in connection with the short-swing transaction.
Billionaire Hedge Funds
